| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Rapport Therapeutics, Inc (NASDAQ:RAPP) IPO will take place June, 07 on the NASDAQ exchange under the ticker RAPP.
The company is offering shares at an expected price between $16.00 and $18.00 per share with an insider lock-up period of 180 days ending on December 04, 2024.
See also: Benzinga IPO Calendar
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system ("CNS") disorders. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor associated proteins ("RAPs"), the latter of which play crucial roles in regulating receptor expression and function
See also: Benzinga's Most Shorted Stocks
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: RAPP
